JP Morgan Maintains Overweight on Maze Therapeutics, Lowers Price Target to $51
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ:MAZE) with a Overweight and lowers the price target from $53 to $51.
JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ:MAZE) with a Overweight and lowers the price target from $53 to $51.
